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1. Introduction
Cancer is a malignant disease in which abnormal cells
divide in an uncontrolled way, leading to the formation of
a solid mass referred to as tumor or to blood cancers.[1]
According to the WHO (http://www.who.int/cancer/en/),
cancer is one of the leading causes of mortality worldwide
and was responsible for 8.8 million deaths in 2015. The most
prominent cytotoxic drug class is cisplatin (CDDP), which is
still one of the most applied chemotherapeutic agents in
clinics. Besides CDDP, a series of other drugs have shown
their anticancer potential by temporarily alleviating symp-
toms, prolonging the lifespan of patients and in rare cases
even curing the cancer.[2] However, all of them suffer from
major disadvantages such as severe side effects owing to lack
of selectivity, low efficiency against some cancer types, and
low bioavailability. Therefore, there is still the quest for
alternative drugs selectively incapacitating cancer cells with-
out severely damaging normal cells.
In this context, polyoxometalates (POMs), which are
described as clusters of transition metal (W, Mo, V, Nb) and
oxygen atoms, have in the last decades been found to be
promising anticancer drug candidates. POMs exhibit an
overwhelming diversity in size and structure (Figure 1) with
outstanding properties and functions.[3] They have been
studied vigorously and are used in a wide range of applica-
tions such as catalysis,[4] nanoscience,[5] macromolecular
crystallography,[6–8] and medicine.[9, 10] The anticancer activity
of POMs was first mentioned in 1965, when Mukherjee
described the in vivo application of a mixture named PTMC,
a combination of H3[PW12O40], H3[PMo12O40] and caffeine, on
patients suffering from gastrointestinal cancer.[11] Despite
leading to the complete disappearance of tumors in four
patients, PTMC was not subjected to further clinical studies.
Years later, in 1974, Jasmin et al. described the inhibitory
effect of (NH4)17Na[NaSb9W21O86] against sarcoma virus-
induced tumors.[12] Since then, consid-
erable attention was paid to the devel-
opment of biologically active
POMs.[9, 13] In this regard, especially
Yamase and co-workers performed
some important pioneering work by
synthesizing [NH3Pr
i]6[Mo7O24] (PM-
8) that has been evaluated for its
in vitro and in vivo anticancer activities.[14, 15] PM-8 was
highly efficient in vivo by suppressing the tumor growth in
different mice models being partially more active than
approved drugs such as 5-fluorouracil (5-FU) and nimus-
tine.[16] In 1991, Fujita et al. tested 50 POMs for their
anticancer activity, among them different variants of PM-8,
and found only four promising compounds, namely PM-8, the
reduced form of PM-8 (PM-17), [NH3Pr
i]6[Mo7O26] (PM-26),
and Na5[IMo6O24] (PM-32).
[17] Yamase noticed that the






toxic in comparison to PM-8. Therefore, he proposed
a mechanism for the anticancer activity of PM-8 which
involves its reduction to PM-17 and its re-oxidation in which
course the tumor cells are reduced and thus killed.[19] The
proposed mechanism seemed reasonable as PM-8 can be
biologically reduced by FMN, an electron carrier responsible
for the electron transport from NADH to coenzyme Q.[19,20]
Polyoxometalates (POMs) are an emerging class of inorganic metal
oxides, which over the last decades demonstrated promising biological
activities by the virtue of their great diversity in structures and prop-
erties. They possess high potential for the inhibition of various tumor
types; however, their unspecific interactions with biomolecules and
toxicity impede their clinical usage. The current focus of the field of
biologically active POMs lies on organically functionalized and
POM-based nanocomposite structures as these hybrids show
enhanced anticancer activity and significantly reduced toxicity towards
normal cells in comparison to unmodified POMs. Although the anti-
tumor activity of POMs is well documented, their mechanisms of
action are still not well understood. In this Review, an overview is given
of the cytotoxic effects of POMs with a special focus on POM-based
hybrid and nanocomposite structures. Furthermore, we aim to provide
proposed mode of actions and to identify molecular targets. POMs are
expected to develop into the next generation of anticancer drugs that
selectively target cancer cells while sparing healthy cells.
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This process is coupled with the generation of ATP and
therefore the proposed redox-cycle mechanism is based on
the inhibition of ATP formation.
Despite the success story of PM-8 and others, purely
inorganic POMs mostly suffer from high and long-term
toxicity, impeding their clinical application.[21] Therefore, the
research focus is switching from inorganic POMs to POM-
based organic-inorganic hybrids as the functionalization and/
or encapsulation of POMs with organic moieties not only
reduced the toxicity of the POM in most cases but also
increased its anticancer activity. In this Review, we report on
the development and recent advances in the synthesis of
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Figure 1. Overview of common POM archetypes. a) Keggin, b) Wells–Dawson, c) Anderson, d) Lindqvist, e) decavanadate, f) sandwich Keggin,
g) double Keggin, h) heptamolybdate, i) a- and j) g-octamolybdate, k) Preyssler, l) Strandberg, and m) Krebs-type structure. Blue polyhedra are
{MO6} (M =any addenda atom), light green polyhedra {XOn} (X = heteroatom), light green spheres sodium, light blue polyhedra {WO6}, light
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POMs with proven antiproliferative activity. Our focus lies
especially on organically modified POMs and POM-based
nanocomposites and their potential application as chemo-
therapeutic agents. This Review provides a comprehensive
overview of proposed molecular targets and mode of actions.
Moreover, we present an outlook discussing why POMs,
despite their disadvantages, are still potential next-generation
metallodrugs in the combat against cancer.
2. Anticancer Activity of Polyoxometalates
2.1. Anticancer Activity of Purely Inorganic Polyoxometalates
After the auspicious results from PM-8 and other
polyoxomolybdates (POMos; Supporting Information,
Table S1), interest in this type of compounds peaked, leading
to a vast number of biologically active POMs (Supporting
Information, Tables S1–S3). In 2005, Liu et al. tested the
antiproliferative activity of in total 21 POMs against KB cells
(HeLa derived human oral carcinoma). The results revealed
that the structure has a major impact on the antitumoral
activity as the polyoxovanadate (POV) K7[NiV13O38] (IC50 =
0.29–0.36 mgL@1) and the heptamolybdate PM-8 (Figure 1h,
IC50 = 0.40 mgL
@1) were the most active POMs followed by
a series of Anderson POMs (Figure 1c, IC50 = 0.45–
0.53 mg L@1), whereas POMs exhibiting the Keggin (Fig-
ure 1a, IC50 = 1.9–43.5 mg L
@1) and Wells–Dawson structure
(Figure 1b, IC50 = 34.5–52.3 mgL
@1) were by far the least
active clusters.[22] It is similar with the type of addenda atom as
POVs were slightly more active than POMos followed by the
least active polyoxotungstates (POTs). Mixed-type POMs
showed increased activity when a W atom was substituted by
a V or Mo atom. This is in accordance to the proposed redox-
based mechanism of Yamase as the oxidation power follows
the sequence POVs>POMos>POTs.[23]
The promising antitumor activity of POVs is not surpris-
ing, as the most prominent representative, decavanadate
[V10O28]
6@ (Figure 1e), is known to be highly bioactive,
including excellent antitumor activity,[24–26] owing to its high
affinity towards important enzymes such as kinases,[27]
actin,[28] and P-type ATPases.[29, 30] A series of POVs exhibited
strong antitumor activity against different cancer cell lines
(Supporting Information, Table S3) such as
K12[V18O42(H2O)], of which activity against the breast adeno-
carcinoma cell line MCF-7 was superior to that of the
approved drug 5-FU (inhibitory rate at 250 mm ca. 70 % vs. ca.
20%).[31] The CoII containing decavanadate Na4Co(H2O)6[
V10O28] was the only POV that was tested in vivo inhibiting
the tumor growth in murine liver cancer Hep-A-22 bearing
mice by 47.1% at a dose of 6 mgkg@1.[24] The activity
resembled that of 5-FU (80.5 % at 20 mgkg@1), however, the
POV was clearly better tolerated by mice, as the body weight
was less-affected by the polyanion. Besides its in vivo activity,
the POM inhibited in vitro the proliferation of human
hepatocellular (SSMC-7721) and ovarian (SK-OV-3) carci-
noma cell lines (IC50 = 0.3 and 0.2 mgmL
@1). Comparison with
Na6[V10O28] (IC50 = 9.9 and 18.9 mgmL
@1) revealed that the
introduction of CoII as counterion has considerably increased
the activity of decavanadate.
The anticancer activity of other POMs also benefited from
the incorporation of CoII or other transition metals (TMs).
For example, the addition of CoII to the trilacunary Keggin
POM [SbW9O33]
9@ led to the formation of the sandwich
structure (Figure 1 f) Na9[{Na(H2O)2}3{Co(H2O)}3(a-B-
SbW9O33)2], of which antiproliferative activity against
human ovarian (SK-OV-3, IC50 = 33.3 mg mL
@1), hepatocellu-
lar (SSMC-7721, IC50 = 20.7 mgmL
@1) and liver cancer cells
(Hep-G2, IC50 = 9.3 mgmL
@1) was significantly higher than
that of the parent POM (IC50 = 203.6, 219.6 and
214.0 mgmL@1).[32] The increase in anticancer activity was
explained by the CoII induced changes in polarity, acidity, and
redox properties of the POM unit facilitating the cell
penetration and target interactions of synergistic CoII-POM
systems.





(H2O)14)(BiW9O33)2] (im = imidazole), showed promising
anti-liver cancer (Hep-G2) activity (Supporting Information,
Table S2).[33] The NiII containing POM was the most active
compound (IC50 = 25.6 mm), followed by the Mn
II and ZnII
containing clusters (IC50 = 30.1 and 32.3 mm), whereas the
CoII-POM (IC50 = 37.3 mm) was the least active one. All tested
POMs performed significantly better than CDDP (IC50 =
66.1 mm) against Hep-G2 cells. However, activity tests using
human hepatocyte (QSG) cells revealed also a significant
activity against normal cells (IC50 = 32.4 mm (Ni
II), 43.2 mm
(MnII), 49.7 mm (ZnII), and 38.5 mm (CoII)). Based on this,
the ZnII containing Krebs-POM was the most selective and
thus clinically most suitable compound.[33] The MnII[34] and
CoII[35] containing Krebs structures were also tested on other
cancer cell lines performing partially better than clinically
approved drugs and were shown to induce apoptosis (Sup-
porting Information, Table S2).
Another POM inducing evidently apoptosis is the CuII
containing double Keggin POT (Figure 1g) K7Na3[Cu4(-
H2O)2(PW9O34)2], which showed inhibitory effects against
both human (MG-63) and rat (UMR-106) bone osteosarcoma
(IC50 = 22 and 81 mm).
[36] The POM increased the intracellular
level of reactive oxygen species (ROS) while reducing that of
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the ROS-scavenger glutathione (GSH) via GSH-POM inter-
actions leading to the dissipation of the mitochondrial
membrane potential and finally to apoptosis. Moreover, the
cytotoxic effect of the POT on MG-63 was higher than that of
CDDP (IC50 = 43 mm).
All of the reported inorganic POMs exhibiting antiproli-
ferative activity are summarized in the Supporting Informa-
tion, Tables S1–S3.
2.2. Anticancer Activity of Inorganic–Organic Hybrid
Polyoxometalates
The functionalization of POMs with organic groups is the
main focus of the field of bioactive POMs, as purely inorganic
POMs generally exhibit toxic side effects and limited cell
penetration owing to their surface characteristics. The intro-
duction of organic moieties into the POM framework can
change its surface, charge, polarity, and redox properties,
leading to a completely new compound with reduced toxicity
and increased cell penetration ability. Organically modified
POMs are in general more stable in aqueous solutions and,
depending on the attached functionality, their interaction with
biological targets are enhanced and more specific.
2.2.1. Organometallo-Substituted Polyoxometalates
Many organometallic molecules possess promising anti-
cancer activities and are thus a good choice for the hybrid-
ization with POMs to develop hybrids with enhanced
biological activity.[37] A series of studies have been published
describing mainly the in vitro antiproliferative activity of
organometallo-substituted POTs containing organotin RSn
(R = C4H7O2, C5H9O2, and NC3H4) or metal–cyclopenta-
dienyl CpMn+ groups (Cp = h5-C5H5, M = Ti
IV, ZrIV, VIV, FeII)
against human cervical (HeLa) and liver (SSMC-7721)
cancer cells (Supporting Information, Table S4).[38–44] The
tested structures were Keggin-, sandwich Keggin-,







(X = heteroatom, m = 1–3). Compounds with attached cya-
noethyltin groups (NC3H4Sn) were more active than those
containing estertin groups (C4H7O2Sn and C5H9O2Sn), sand-
wich-Keggin were superior to Keggin structures, and with
increasing RSn content the antitumor activity was enhanced.
For very closely related compounds the antitumor activity
correlates with their redox potential, that is, the higher the
redox potential, the higher the cytotoxicity. In general, CpMn+
containing POMs exhibited higher antitumor activities than
the RSn structures (Supporting Information, Table S4).[45,46]
The influence of the metal in the CpMn+ group on the
antitumor activity is cancer cell specific as given cells are
more or less susceptible to a certain metal. K6H[(h
5-
C5H5Ti)CoW11O39] was applied orally to human liver
(SSMC-7721), leukemia (HL-60), and colon cancer (HLC)
bearing mice (for 10 d) and significantly decreased the growth
of all tumors exhibiting inhibitory rates of 41.9% (dose =
15 mg kg@1), 50.0 % (100 mg kg@1) and 48.9 % (100 mgkg@1),
respectively.[47] The POT performed better than the clinically
approved drug cyclophosphamide (CP) against SMMC-7721
(inhibitory rate = 37.2% at 36.4 mgkg@1) but was less active
than 5-FU against the other cell lines (56–57.4 % at 15–
30 mg kg@1), however, it was by far the least toxic com-
pound.[47]
The organotin substituted Keggin K3H[{(n-Bu)Sn(
OH)}3GeW9O34] inhibited the tumor growth in the H22
(murine liver cancer) mice model by 62.5 % after 14 d (dose =
300 mgkg@1).[48] The activity was significantly lower than that
of CP (inhibitory rate = 95.5%), however, the drug also
impaired the growth of mice, which is indicative of toxic side
effects, whereas the POM did not. The hybrid showed also
promising in vitro activity against a series of other cancer cells
(Supporting Information, Table S4).
The antitumor activity of other organometallo substituted
POMs is listed in the Supporting Information, Table S4.
2.2.2. Polyoxometalate–Drug Hybrids
2.2.2.1. Polyoxometalate-5-fluorouracil Hybrids
The combination of POMs with drug molecules is
a promising strategy in cancer treatment, as POM–drug
hybrids are multi-functional systems capable of interacting
with multiple targets. In this way, the hybrids are less prone to
drug resistance and could exhibit improved activity and
selectivity. The combination of the anticancer drug 5-FU with




led to POT-5-FU hybrids that were more active against the
tumor cell lines HeLa, Hep-G2, and SMMC-7721 than 5-FU
alone, indicating synergistic effects (Supporting Information,
Table S5).[49–51] Furthermore, the hybrids were less toxic
against normal human embryonic kidney cells (HEK-293)
than the free drug. The [PW12O40]-5-FU and [SiW12O40]-5-FU
systems were later extended by the introduction of rare earth
metals (Dy, Eu, Er, Gd, La, Nd, Pr, Sm, Y), which in most
cases did not only lead to an increase in activity (against HeLa
and Hep-G2) but also to enhanced selectivity (Supporting
Information, Table S5).[51–55] However, POM-rare earth metal
complexes (without 5-FU) like K11[L(PW11O39)2] (L = Dy, Er,
Gd, La, Y) were remarkably less active than the correspond-
ing 5-FU containing hybrids, indicating no significant synergy
between the POM and rare earth metals.
2.2.2.2. Polyoxometalate–Bisphosphonate Hybrids
The Dolbecq group investigated the antitumor activity of
a series of POM-bisphosphonate complexes.[56–59] Bisphosph-
onates (BPs) are drugs used to treat osteoporosis and similar
diseases but do also exhibit antitumor activity.[60] BPs have the
general formula H2O3PC(OH)(R)PO3H2 with R determining
their drug efficacy, as, for example, the primary nitrogen
containing alendronate (Ale, R = (CH2)3NH2) is 100–1000
times less active than zoledronate (Zol, R = (H2(C3H3N2)),
which has a heterocyclic amine at position R.[61] POM-BP
complexes are not classical POM-based structures, and the
most studied compounds exhibited the general formulas M6L2
and M4L2X (M = {MoO6}, {WO6}, {VO6}; L = BP and X =
MnII/III, FeIII) (Figure 2). The hybrids were active on human
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non-small cell lung cancer (NCI-H460), glioblastoma (SF-
268), and breast cancer (MCF-7) cells, whereby V-based
complexes were the most active (Supporting Information,
Table S6). Molybdates and tungstates had only noticeable or
good antitumor activity in combination with the most
bioactive BP Zol. Thus, the antitumor activity of the POM-
BP systems correlated with the presence of either V or Zol.
The most potent complexes, not containing V, were
Mo4Zol2Mn
II/III, indicating that the introduction of MnII/III as
heteroatom has a significant effect on the antitumor activity
of these complexes. Mo4Zol2Mn
III was the only POM-BP
complex that was studied in vivo.[59] Applied to the mouse
xenograft model bearing human Ewing sarcoma (SK-ES-1),
Mo4Zol2Mn
III (5 mg/mouse for 28 d) decreased the tumor
volume by about 85 % in comparison to the control (buffer).
Furthermore, the complex did not reduce the body weight,
indicating the absence of harmful effects on mice. Regarding
the mechanism, amino group containing BPs are known to
inhibit the prenylation of important proteins like small
GTPases, which are involved in tumor growth, and therefore
the POM-BP complexes could follow a similar mechanism
(see Section 3.2).[62]
2.2.2.3. Polyoxometalate–Quinolone Hybrids
Another example for POM-drug complexes with antitu-
moral properties are POM–quinolone antibiotic struc-
tures.[63–68] Quinolone antibiotics such as pipemidic acid
(PPA) inhibit the growth of gram-negative bacteria by
preventing DNA from unwinding and duplicating. Owing to
their structure, which contains abundant O and N donors,
quinolones are excellent multidentate ligands and thus ideal




4@ and the octamolybdates b-
and d-[Mo8O26]
4@ were decorated with different quinolone
antibiotics such as PPA, enrofloxacin (enro), norfloxacin
(norf), and enoxacin (eno). In most cases a TM (CuII, ZnII,
NiII, CoII) was additionally incorporated into the structures,
leading to different POM-TM-quinolone complexes, where
the POM acts as a mono- or bidentate inorganic ligand and
the quinolone as an organic ligand for the TM. In POM–TM–
quinolone systems, the POM is covalently linked to the TMs
and quinolones, whereas in TM-lacking compounds the
quinolones are clustered around the POM via noncovalent
interactions. The complexes exhibited mixed results against
a series of cancer cell lines as only a couple of them showed
good antitumor activity, whereas the vast majority showed no
to moderate activity (Supporting Information, Table S7).
Depending on the used constituents, complexes with different
coordination modes and POM–quinolone interactions were
obtained. In general, hybrids possessing a TM center with
a five-coordinate geometry were less active than those with
a six-coordinated TM (Figure 3a), and systems with a biden-
tate POM ligand (one POM binding two TMs, Figure 3b,
right) were more active than those having a monodentate
POM ligand. Thus, it was proposed that certain structural
constellations might favor the delocalization of the whole
electrons, which increases hybrid–tumor interactions, whereas
other constellations lead to rather unsymmetrically polarized
POMs with quenched activity.[64] Furthermore, it was sug-
gested that structures like [Cu(PPA)2]2[PW12O40], where the
POM unit is surrounded by quinolones, are less active as the
interaction of the POM with tumor cells is sterically hindered
Figure 2. General structure of the POM-BP compounds M6L2 and
M4L2X. L= bisphosphonate side chains, which are depicted at the
bottom. The phosphonate group is depicted in ball and stick mode
(orange spheres, phosphorous; red spheres, oxygen). Blue polyhedra
are {MO6} (M= V, Mo, W), purple polyhedra {XO6} (X =Fe
III, MnII/III),
green sticks carbon, red spheres oxygen.
Figure 3. Structures of POM–quinolone hybrids. a) [Cu2(Enro)3H2O][
SiW12O40] (left) and H2[Ni(Enro)2][SiW12O40] (right). The adjacent POM
found in the crystal structure of H2[Ni(Enro)2][SiW12O40] is indicated by
a transparent molecule; however, in solution this site is most probably
occupied by a solvent molecule. b) [HPPA]5[PW11CdO39] (left) and
[Cu(PPA)2]2[PW12O40] (right). Red arrows indicate the accessible inter-
action sites. Light blue polyhedra are {WO6}, orange polyhedra {PO4},
green sticks carbon, dark blue sticks nitrogen, dark green sticks
fluorine, brown spheres copper, green sphere nickel, yellow sphere
cadmium, red sticks and spheres oxygen.
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in comparison to complexes containing freely accessible
interaction sites (Figure 3b).
2.2.3. Anderson Polyoxometalate–Biomolecule Hybrids
Regarding the organic modification of POMs, the Ander-
son archetype is one of the best studied systems as it can be
easily tris-functionalized (tris = tris(hydroxymethyl)amino-
methane) leading to an amino group(s) bearing structure,
which can be further modified by simple amidation.[69–72] Thus,
the Anderson structure represents an ideal basis for the
synthesis of versatile POM-ligand complexes. Yang et al.
synthesized a series of POM-biomolecule conjugates by
grafting different bioactive receptor ligands to the surface of
the Anderson POM to improve the selectivity and thus the
antitumor activity of the POM.[73] The tris-modified Ander-
son-type molybdate {MnMo6O18[(OCH2)3CNH2]2}
3@ (tris-
POM-tris) was used as starting molecule to attach cholic
acid (CA), dehydrocholic acid (DHCA), O-succinyl-choles-
terol (CHOL), 6-O-(3-carboxypropanoyl)-1,2:3,4-di-O-iso-
propylidene-b-d-galactopyranose (GAL) and adipic acid
(AA) to the POM (Figure 4).
CA and DHCA are bile acids that target the farnesoid X
receptor (FXR), a nuclear receptor, which induces cell death
in some breast cancer cell lines upon activation.[74] CHOL is
a precursor for the synthesis of bile acids and building block of
the cell membrane, which might be helpful for cancer cell
targeting. GAL is the diacetal form of galactose, which is
recognized by some lectins of which expression is strongly
associated with tumorigenesis and thus could enhance cancer
cell selectivity.[75] AA is an organic dicarboxylic acid, which
was used for comparison reasons. The cytotoxicity of these
hybrids was tested against the breast cancer cell lines MCF-7
and MDA-MB-231 and the noncancerous breast cell cline
MCF-10A (Supporting Information, Table S8). As expected,
the most effective complexes were CA-POM-CA (IC50 = 55.9,
37.9 and 278.2 mm) and DHCA-POM-DHCA (IC50 = 112.7,
149.0 and > 400 mm) exerting the highest selectivity and
antitumor activity. The remaining complexes were only
weakly or moderately active (IC50 = 204–400 mm). The sig-
nificant synergy between the POMo and CA/DHCA derives
from the capability of all constituents to induce apoptosis,
whereby the bile acids impart selectivity to the complex by
targeting FXR.
2.2.4. Polyoxometalate–Amino Acid Hybrids
Amino acids are promising organic units to functionalize
POMs owing to their structural and chemical variety and
biocompatibility. A string of amino acid functionalized POMs
was synthesized and some of them showed promising
anticancer activity (Supporting Information, Table S9).
The g-isomer of octamolybdate, g-[Mo8O26]
4@ (Figure 1 j),
was modified with different amino acids, yielding the hybrids
Na4[Mo8O26(ala)2], Na4[Mo8O26(glygly)2], [Hmorph]4[-
Mo8O24(OH)2(met)2], and [Hmorph]4[Mo8O24(OH)2(ala)2]
(ala = alanine, glygly = glycylglycine, morph = morpholine,
met = methionine) that selectively inhibited the cell growth
of human liver and breast cancer cells (Hep-G2 and MCF-7)
while showing no significant effect on other cancer cell lines
(Supporting Information, Table S9).[76] The antiproliferative
activity of these hybrids was not cell-cycle related and thus
not induced by apoptosis. Cartuyvels et al. later proposed that
the antitumor activity of such hybrids and octamolybdate in
general could be related to the hydrolysis of ATP as they
observed ATP hydrolysis in the presence of Na4[Mo8O26(
pro)2] (pro = proline) at acidic pH (< 5.8).
[77] However, the
role of ATP hydrolysis during cancer progression is elusive as
ATP exhibits biphasic actions, that is, it has both tumor
promoting and inhibitory effects.[78]
The glycine-decorated POMo K2Na[AsMo6O21(gly)3]
(gly = glycine) showed weak to moderate inhibitory effects
against human lung carcinoma cells (A-549, IC50 = 330.2 mm),
which were still superior to that of 5-FU (ca. 40% inhibition
at 1 mm).[79] However, the arsenomolybdate was later found
to be highly active on the human leukemia cell lines HL-60
and U937 (IC50 = 8.6 and 14.5 mm ; Supporting Information,
Table S9) being more active than all-trans retinoic acid
(ATRA, IC50 = 20.8 mm vs. HL-60 and 14.9 mm vs. U937),
a clinical anticancer drug, but less active than the antileuke-
mic agent As2O3 (IC50 = 6.4 mm vs. HL-60 and 8.8 mm vs.
U937).[80] However, As2O3 is also highly cytotoxic towards
normal cells such as human umbilical vein endothelial cells
(HUVECs) for which it exhibits an alarming IC50 value of
5.6 mm,[81] while K2Na[AsMo6O21(gly)3] has no significant
activity on HUVECs (IC50 = 889.2 mm). The selective anti-
leukemic activity of the hybrid might arise from AsIII but its
low toxicity towards normal cells in comparison to As2O3
renders it a promising alternative for the treatment of
leukemia.
Other amino acid functionalized POMs with antitumor
activity are listed in the Supporting Information, Table S9.
Figure 4. Biomolecule-functionalized Anderson structures. Cyan poly-
hedra are {MoO6}, magenta polyhedra {MnO6}, green sticks carbon,
dark blue sticks nitrogen, red spheres oxygen.
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2.2.5. Organically Functionalized Strandberg-type Polyoxometa-
lates
The Strandberg-type POM, [Mo5P2O23]
6@ (Figure 1 l), is
a small POM with a very high charge density, making it ideally
suited to interact with cationic units such as organometallic
compounds. The Strandberg POM–benzimidazole (biz)
hybrid [Hbiz]5[HMo5P2O23] showed cytotoxic effects against
human bone narrow neuroblastoma (SHY5Y) cells (IC50 =
43 mm).[82] Biz is a well-known pharmacophore of which
derivatives are active against several cancer types.[83]
[Hbiz]5[HMo5P2O23] is highly selective towards neuroblas-
toma cells as it did not show any significant activity against
other cancer or normal cell lines (Supporting Information,
Table S10). The anti-SHY5Y activity of the hybrid was
inferior to that of pure biz (IC50 = 28.7 mm) but biz was also
highly toxic on normal cells (IC50 = 21.5 mm vs. EVC-304),
making the hybrid considerably more valuable from a phar-
macological point of view.
Another study reporting Strandberg-type hybrids
describes the antitumor activity of [Cu(pia)2(H2O)2]2H2[
P2Mo5O23], [Cu(pia)2 (H2O)]H2[Cu(pia)2(P2Mo5O23)] and
[Cd(pia)2(H2O)2]2H2[P2Mo5O23] (pia = pyridine-2-carboxa-
mide; Supporting Information, Figure S1).[84] All of the
compounds exhibited promising activity against human
hepatoma Hep-G2 and SMMC-7721 cells and colorectal
carcinoma HCT-116 cells (IC50 = 2.7–35.5 mm), with the
exception of [Cu(pia)2(H2O)2]2H2[P2Mo5O23], which was not
active on HCT-116 (Supporting Information, Table S10).
[Cu(pia)2(H2O)]H2[Cu(pia)2(P2Mo5O23)] was the most
tumor selective compound in this study, as its activity against
normal human liver cells (HL-7702) was 3–17 times lower
than that against the tested tumor cells. Despite having similar
structures, [Cu(pia)2(H2O)]H2[Cu(pia)2(P2Mo5O23)] and
[Cd(pia)2(H2O)2]2H2[P2Mo5O23] showed clearly distinct cyto-
toxic behavior emphasizing the importance of the TM type.
Furthermore, the coordination mode of the TM is also highly
important as the activity of the two CuII containing hybrids
differed remarkably, which is in accordance with the results of
the POM-TM-quinolone hybrids (Section 2.2.2.1).
2.2.6. Organoimido- and Benzoyldiazenido-Functionalized Hex-
amolybdates
Organoimido and benzoyldiazenido substituted hexamo-
lybdates (Figure 1 d) exerted inhibitory effects against human
leucocythemia K-562 cells (Figure 5a,b; Supporting Informa-
tion, Table S11). The former group has the general structure
(TBA)2[Mo6O18(/NAr)] (TBA = tetra-n-butyl ammonium,
Ar = aryl group), whereas that of the latter is
(TBA)3[Mo6O18(=N=NCOAr)]. The aromatic ring in both
systems can be variously substituted providing the ability to
attach a wide range of organic compounds to the POM
core.[85–87] The organoimido derivates were slightly more
active than the benzoyldiazenido bearing POMs as the former
group is more redox-active. Another hybrid group, namely
(TBA)2[Mo6O19@n(/NC10H15)n] (NC10H15 = amantadine, n =
1–3, Figure 5c) containing one or more aliphatic organoimido
groups, showed moderate anti-breast cancer activity (inhib-
ition rate = 48.3% at 100 mg mL@1 vs. MCF-7 cells) but
promising effects against malignant glioma U-251 cells
(IC50 = 31.1 mm).
[88, 89]
However, the most interesting organoimido substituted
POM, regarding its anticancer activity, is POM-AMB-acy
(AMB = 2-amino-3-methylbenzoxyl group, acy = N-acylur-
eido group) (Figure 6).[89] The hybrid inhibited the growth
of U-251 cells (IC50 = 24.8 mm) and, even more importantly,
was able to cross the blood–brain-barrier in vivo. POM-
AMB-acy represents a degradable compound, where the acy
group was introduced for degradation reasons and AMB as
linker. The hybrid complex stayed intact in medium for
40 minutes before decomposing into the bioactive species
upon acy degradation. According to mass spectrometry the
bioactive species is most likely monomeric MoO4
2@. POM-
AMB-acy induced apoptosis in U-251 cells and was signifi-
cantly more active than the clinically used antiglioma agent
temozolomide (TMZ, IC50 ca. 500 mm).
[90]
2.2.7. Other Inorganic–Organic Hybrid Polyoxometalates
Some organically functionalized polyoxoniobates
(PONbs) were reported to possess promising antitumor
activity (Supporting Information, Table S12). For example,
the two CuII containing undecaniobates, [{Cu(
H2O)L}2{CuNb11O35H4}]
5@ (L = 1,10-phenanthroline, 2,2’-
bipyridine; Supporting Information, Figure S2) exhibited
remarkable antiproliferative activity against K-562 (leuke-
Figure 6. Structure of POM-AMB-acy. For clarity, the structural formula
of AMB (green) and acy (red) is additionally depicted. Cyan polyhedra
{MoO6}, green sticks carbon, dark blue sticks nitrogen, red sticks and
spheres oxygen.
Figure 5. General structure of the aromatic organoimido (a), benzoyl-
diazenido (b), and aliphatic organoimido-substituted hexamolybda-
tes (c). Cyan polyhedra {MoO6}, green sticks carbon, dark blue sticks
nitrogen, red sticks and spheres oxygen.
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mia) cells (IC50 = 0.1–0.4 mm).
[91] Since pure PONbs are redox-
stable, a redox-based mechanism for their activity could be
excluded. Another example of PONb-based hybrids are the







8O44}] (en = 1,2-diaminoethane; Sup-
porting Information, Figure S3), which showed partially
high antiproliferative activity against the human gastric
cancer cell lines SGC-791, SC-1680, and MG-63 (IC50 = 0.7–
20.5 mm).[92]
Hybridization of the photosensitizing agent pyridinium
chlorin with [SiMo12O40]
4@ led to a significant improvement of
its phototoxicity against A-549 cancer cells.[93] The increased
photoactivity of (chlorin)4[SiMo12O40] (IC50 = 6.6 mm) in com-
parison to sole chlorin (IC50 > 20 mm) is based on the POM-
mediated increase in the intracellular photogeneration of
ROS (1O2) and improved cellular uptake of the complex.
Zhang et al. synthesized the homochiral POM anion
{CoSb6O4(H2O)3[Co(hmta)SbW8O31]3}
15@ (hmta = hexame-
thylenetetramine) via chiral symmetry breaking and asym-
metric autocatalysis obtaining both racemic and enantiopure
(D- or L-enantiomer) POM complexes.[94] The racemic and
enantiopure hybrids exhibited similar anticancer activity
against eight cancer cell lines, which were significantly
higher than that of the achiral precursor [NaSb9W21O86]
18@
(Supporting Information, Table S12). The compounds
showed high selectivity towards the ovarian cancer cell lines
A2780 and OVCAR-3 (IC50 = 0.8–4.5 mm) and were also
active on the CDDP-resistant cell line A2780cisR (IC50 = 4.4–
4.5 mm).
The anticancer activity of other inorganic–organic hybrids
are summarized in the Supporting Information, Table S12.
2.3. Anticancer Activity of Polyoxometalate-based
Nanocomposites
The encapsulation of drugs is an important area in
biomedicine, as the resulting nanocomposites bring many
advantages such as enhanced drug stability, delivery, and
activity and the extension of the bioactivity by protecting the
drug from premature degradation, which is also associated
with minimal side effects.[95] Using this system, the drug is in
most cases released slowly and gradually leading to a pro-
longed time window within which the therapeutic level of the
drug is sustained. In this way, the pharmacokinetic behavior
of a series of POMs was partially dramatically improved.
2.3.1. Polyoxometalate–Chitosan Nanocomposites
POM–chitosan hybrids are one of the most studied POM-
based nanocomposite systems.[26] Chitosan (CT) is a linear
polysaccharide obtained by the N-deacetylation of chitin and
one of the most widely applied natural polymers in drug-
delivery studies. CT-based systems are ideal in terms of
extended drug release, as CT is degraded in the human body
by several enzymes, leading to a controlled release.[96]
Biocompatibility studies showed that the nanocomposites
{Co4(H2O)2(PW9O34)2}–CMC and {Eu(SiW11O39)2}–CMC
(CMC = carboxymethyl chitosan) did not show any activity
against HeLa cells even at high concentrations (2 mgmL@1)
and long incubation times (up to 48 h).[97, 98] Furthermore,
{Eu(SiW11O39)2}–CMC undergoes fast cellular uptake (within
1 h), confirming the toxicity reducing and cellular transport
enhancing effect of CT. Comparison between the Keggin-type
{CoTiW11O40}–CMC and {CoTiW11O40}–TMC (TMC = tri-
methyl chitosan) hybrids revealed that the carrier properties
of the positively charged TMC are superior to that of its
negatively charged counterpart CMC.[99] The TMC matrix
had a circa 6 times higher POM content, owing to its positive
charge and the associated direct electrostatic interactions, and
it was more readily uptaken by cells. The reason for this was
attributed to the smaller particle size of the POM-TMC
hybrid (61 vs. 131 nm), the different morphology and positive
charge facilitating cell penetration. The release profile of
{CoTiW11O40}–TMC showed a slow but steady POM release
(ca. 15%) over 24 h. Moreover, the TMC nanocomposite
exhibited cytotoxic effects on HeLa cells (inhibitory effect =
50% at 12.5 mg mL@1, 5 h), whereas the parent POM was
rather inactive (ca. 10% at 50 mgmL@1, 24 h).
{Gd(W5O18)2}–CTsiRNA nanospheres possess high potential
as radiosensitizers for synergistic radiotherapy and gene
therapy as they remarkably reduced the radioresistance of
human hepatocellular carcinoma cells (BEL-7402) in vitro
and in vivo.[100] Radiotherapy is a clinically applied cancer
treatment method, which utilizes high-intensity ionizing
radiation to inhibit tumor growth by the generation of
cytotoxic ROS. However, cells in general possess high
amounts of reducing agents such as GSH to combat the
production of ROS and, even more important, tumor cells are
highly hypoxic minimizing the available amount of activat-
able oxygen and thus limiting the therapeutic effect of
radiotherapy. Hypoxia is lethal to all cells; therefore, tumors
develop a set of responses to outstrip their blood supply to
adapt to the stressful hypoxic environment.[101] The master
mediator of this response is the hypoxia-inducible factor 1a
(HIF-1a).[102] Therefore, the authors synthesized a CT-based
system consisting of the ROS-level increasing [Gd(W5O18)2]
9@
and HIF-1a siRNA, which interferes with the expression of
HIF-1a, to reduce the radioresistance of cancer cells.
{Gd(W5O18)2}–CTsiRNA in combination with X-ray radiation
induced significant cell late apoptosis/necrosis response in
both HeLa and BEL-7402 cells (33.6 and 28.8%), whereas the
same hybrid in absence of either X-rays (10.9 and 14.4%) or
siRNA ({Gd(W5O18)2}–CT, 14.4 and 15.9 %) showed clearly
lower apoptotic effects. The in vivo experiment using BALB/c
mice inoculated with BEL-7402 cells (injection every second
day for 25 d) confirmed the in vitro results. Treatment with
{Gd(W5O18)2}–CTsiRNA under X-ray radiation did almost
completely suppress the tumor growth as the relative tumor
volume (the tumor volume measured/initial tumor volume =
V/V0) was about 1 (V/V0 of control ca. 25). The hybrid had no
reducing effects on the body weight, indicating no significant
systemic toxicity. The suggested mechanism is described in
Section 3.2.5.
Electrostatically driven pH-responsive supramolecular
hydrogels consisting of the trilacunary Wells–Dawson
[P2W15O56]
12@, chitosan hydrochloride (CTCl),[103] or
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CMC[104] and poly(methacrylic acid) (PMMA) were antipro-
liferatively active on breast and cervical cancer cells (MCF-7
and HeLa) with minimal effects on normal Vero cells
(Figure 7; Supporting Information, Table S13). Hydrogels
are highly hydrated polymeric networks, including both
covalent and non-covalent interactions, and are ideal to
mimic native tissues owing to their soft consistency, porosity,
and stability. At the maximum applied concentration of
35 mg mL@1 the hydrogels were slightly less active against
both MCF-7 and HeLa (inhibitory effect ca. 72–77 and 68–
70%) than the free POM (ca. 80 and 85 %) and the
chemotherapy agent doxorubicin (DOX, ca. 77 % against
both cells) but clearly more biocompatible. The incorporation
of the pH responsive agent MMA led to a pH-controlled
swelling of the gel and thus to a sustained POM release.
In vivo experiments using rabbits revealed a maximum toler-
able dose of 4000 mgkg@1 and no significant histopathological
effects on important organs.
Other POM-CT hybrids with anticancer activity are
summarized in the Supporting Information, Table S13.
2.3.2. Polyoxometalate–Starch Nanocomposites
Starch is a polysaccharide consisting of glucose units
linked by a-1,4-gylcosidic bonds that is extensively used in
pharmaceutics as a drug carrier owing to its biocompatibility,
biodegradation, and stability properties.[105] The starch-encap-
sulated POM (SEP) {CoTiW11O40}–SEP showed increased
anti-cervical (HeLa) and anti-leukemia (HL-60) activity
compared to the free Keggin POM (Supporting Information,
Table S14).[106] The increase in the antitumoral effect was
attributed to the enhanced cell penetration ability of the
starch complex, which was quantified revealing a HeLa cell
penetration efficiency of 83.1% being more than three times
higher than that of the parent POM (25.5 %). However,
{CoTiW11O40}–SEP was stable for only 4 h (pH 7.4) before
undergoing decomposition. Similar penetration efficiencies
were obtained for the dimeric titanotungstosilicate
[Si2Ti6W18O77]
14@ and its starch encapsulated nanoparticles
(24.6 vs. 87.2 %), confirming the starch-mediated improve-
ment in cell penetration.[107] The in vitro release profile
revealed an initial burst effect within the first 2–3 h, where
weakly bound POMs at the nanoparticle surface are quickly
released (ca. 40% of POM), followed by a sustained release.
Such an initial burst effect, which can lead to local and toxic
overdoses of POM, was not observed for CT-based nano-
particles. In vitro antitumor tests showed that the IC50 values
of {Si2Ti6W18O77}–SEP against HeLa and HL-60 cells (3.2 and
8.1 mgmL@1) were significantly lower than that of the free
POM (46.4 and 60.5 mgmL@1). The in vivo activity of the SEP
in H22 bearing rats (inhibitory rate = 44.2% at 96 mgkg@1)
was also superior to that of the parent POM (40 % at
200 mgkg@1) but inferior to that of the clinical drug CP (44%
at 36.4 mgkg@1). The LD50 value of [Si2Ti6W18O77]
14@ was
increased from 1803 to at least 2855 mgkg@1 upon starch
encapsulation.
The anticancer activity of further POM-SEP systems is
summarized in the Supporting Information, Table S14.
2.3.3. Polyoxometalate–Liposome Nanoparticles
Liposomes are small spherical vesicles possessing at least
one lipid bilayer. Owing to their ability to minimize the
systemic toxicity of a hosted drug and protecting it from early
degradation, liposomes are ideal to modify the pharmacoki-
netic behavior of POMs.[105] The liposome-encapsulated POM
(LEP) {Si2Ti6W18O77}–LEP was synthesized in two different
sizes, namely 60 and 150 mm, with the smaller nanoparticles
having a slightly higher activity against HeLa and HL-60 cells
(IC50 = 3.2 and 4.6 mgmL
@1 vs. 4.4 and 5.2 mgmL@1), which
might be attributed to the facilitated cell penetration of the
smaller particles.[108] The antitumor activity of this LEP was
comparable to that of its starch encapsulated counterpart
{Si2Ti6W18O77}–SEP. Studies with other POMs like the Keggin
structures [SiM11O39Co(H2O)]
6@ (M = Mo, W) and
[PV2Mo10O40]
5@, which were encapsulated by both biomate-
rials, revealed that the corresponding LEPs (IC50 = 4.5–
13.4 mm) and SEPs (IC50 = 5.2–14.5 mm) exhibit similar anti-
tumor activities (Supporting Information, Tables S14,
S15).[109–111] Regarding the drug release, {CoTiW11O40}–LEP,
which has anticancer activity in hepatocellular cancer and
leukemia cells, SSMC-7721 and HL-60 (IC50 = 3.5 and
3.6 mm), showed a slow and sustained release (ca. 20%
POM release).[112] In comparison, the same POM encapsu-
lated by TMC showed a similar release profile but with
a faster initial release, whereas the starch hybrid of this POM
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decomposes after several hours, indicating that the liposome
matrix is the most suitable carrier for [CoTiW11O40]
8@.
The penetration efficiency of LEPs is similar to that of the
two biopolymers discussed before as about 81% of
{SiTiW11O40}–LEP was found inside HeLa cells and
HUVECs, whereas the penetration efficacy of the POM
alone was only about 25%.[113] The anticancer activity of
{CoTiW11O40}–LEP against KB and HeLa cells (IC50 = 2.2 and
2.3 mgmL@1) was higher than that of the free POM (IC50 =
34.5 and 47.3 mgmL@1) and 5-FU (Supporting Information,
Table S15). However, its in vivo inhibitory effect on the tumor
growth in HL-60 bearing rats (42 % at 26.4 mgkg@1) was
inferior to that of 5-FU (58.3 % at 25 mgkg@1) but still
remarkably higher than that of the pristine POM (13 % at
200 mgkg@1). The LD50 value of [SiTiW11O40]
6@ was increased
from 349 to 2003 mgkg@1 upon liposome encapsulation.
The hybrid POM [(C16H33)2NCONH(
CH2)3SiNaP5W29O110]
14@ (P5W29-lipid), which is composed of
the mono-lacunary Preyssler anion [NaP5W29O107]
14@ with an
attached long-chain organoalkoxysilane lipid, exhibited
promising antiproliferative activity against human colon
adenocarcinoma cells (HT-29).[114] The lipid covalently binds
to the lacuna of the POM via its organosilicate functionality
giving the hybrid an amphiphilic character. The hybrid
spontaneously self-assembles into a liposome with the POM
forming the lipid bilayer (Figure 8). Although the parent
[NaP5W30O110]
14@ (Figure 1k) has already a strong anti-HT-29
activity (IC50 = 3.6 mm), it was even improved by the lipid-
hybridization (IC50 = 2.1 mm). Owing to its special structure,
the hybrid formed stable complexes with biotinylated sBLM,
a natural membrane mimetic. Therefore, an uptake mecha-
nism was proposed, where the P5W29-lipid binds to the
membrane and then intercalates into it forming a transient
hybrid-membrane complex, which finally releases the POM
within the cytoplasmic space.
2.3.4. Polyoxometalate–Silica Nanocomposites
Silica-based nanoparticles are promising candidates for
the drug delivery in cancer therapy because their particle size
can be finely tuned to ensure appropriate accommodation of
guest molecules, which is especially true for mesoporous silica
nanoparticles (MSNs).[115] Karimian et al. reported on a com-
plex delivery system consisting of a thiolated MSN as drug
carrier that covalently binds the N-Boc-cysteine-functional-
ized Keggin-type POM [GeV3W9((CH2O)3N-Boc-Cys)O37]
4@
(Boc = tert-butyloxycarbonyl, Cys = cysteine) via a disulfide
bond.[116] The addition of the fluorescent dye fluorescein
isothiocyanate (FITC) to the organic functionality of the
POM yields the final POM-MSN-dye complex, where the
pores of the MSN are capped by the POM and loaded with the
anticancer drug DOX (Figure 9). The redox-responsive
disulfide bond was chosen for selective POM-release as
cancer cells contain elevated levels of GSH, which is able to
cleave disulfide bonds, whereas FITC was attached for
cellular tracking reasons. [GeV3W9O40]
7@ was chosen as
POM unit as it exhibited the highest antiproliferative activity
against human glioblastoma cells (U-87, inhibitory effect =
44% at 50 mgmL@1) among a series of tested POMs,
[XM3W9O40]
n@ (X = Si, Ge; M = V, W, Mo) (Supporting
Information, Table S2). The POM-MSN-dye complex
loaded with different concentrations of DOX exhibited
selective anticancer activity against U-87 cells (inhibitory
effect = 70% at 2 mg mL@1 DOX) as it was significantly less
active on normal cells (ca. 40 % at 2 mgmL@1 DOX).
Compared to the multidrug complex, the antitumor activities
of the sole POM and DOX (ca. 50% at 2 mgmL@1) were
Figure 8. Illustration of the spontaneous assembly of the POM–lipid
hybrid into a vesicle. Light blue polyhedra are {WO6}, orange polyhedra
{PO4}, purple sphere silica, red spheres oxygen.
Figure 9. Representation of the POM-MSN-dye-DOX system. At the
top of the figure the disulfide bond (orange) is intact and the attached
POM-dye (dye =green) hybrid blocks the release of DOX molecules
(big red spheres) from the MSN pores. After disulfide cleavage by
GSH, the POM-dye hybrid and DOX are released. Light blue polyhedra
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clearly inferior. As expected the activity of the hybrid
increased in a DOX concentration-dependent manner with
the DOX release being GSH concentration-dependent.
The anticancer activity of other silica-based POMs is
summarized in the Supporting Information, Table S16.
2.3.5. Other Polyoxometalate-based Nanocomposites
{Mo7O24}–gelatin nanoparticles showed promising anti-
cancer activity in vitro and in vivo.[117] Gelatin is a natural
polymer that is highly biocompatible and owing to its
zwitterionic character it forms a stable hydrophobic complex
with heptamolybdate (Figure 1 i). At high concentrations, the
{Mo7O24}–gelatin nanoparticles exhibited cytotoxicity to
human gastric cancer cells (BGC-823) in vitro, which was
significantly higher than that of the plain POM (inhibitory
rate = 75 vs. 20% at 0.5 mgmL@1), however, at lower concen-
trations (< 0.25 mgmL@1) the hybrid was inactive. The in vivo
experiment using ICR mice inoculated with murine liver
cancer cells (H22) confirmed the tumor-inhibiting potential of
the hybrid as the relative tumor volume (V/V0) was 14.5 upon
treatment with 20 mgkg@1 of {Mo7O24}–gelatin for 9 d,
whereas V/V0 of the control and the free POM
(100 mgkg@1) was about 35 and about 27, respectively. All
tumor-bearing mice died within 31 days in the control group,
whereas the hybrid group (100 mgkg@1) exhibited a survival
rate of 60% after 40 d (ca. 20% in the heptamolybdate group,
100 mgkg@1).
The PtIV substituted Keggin-type POM
[PW11O40(SiC3H6NH2)2Pt
IV(NH3)2Cl2]
3@ was synthesized as
a pharmacological prodrug that has to undergo PtIV to PtII
reduction to be activated.[118] However, the cell penetration
properties of this organoplatinum substituted POM are
limited leading to a low in vitro anticancer activity (inhibitory
effect ca. 35% at 20 mm vs. HT-29). Therefore, the prodrug
was encapsulated with 1,2-distearoyl-sn-glycero-3-phosphoe-
thanolamine-N-[methoxy(polyethylene glycol)-2000] (DSPE-
PEG2000) yielding the nanocomposite Pt
IV-PW11-DSPE-
PEG2000. As expected, the hybrid was readily internalized
into HT-29 cells, which was also reflected in its anti-HT-29
activity (inhibitory effect = 85 % at 20 mm) being clearly
superior to that of CDDP (ca. 45 %). The nanocomposite
showed low toxicity towards normal HUVECs (inhibitory
effect ca. 30% at 50 mm), whereas CDDP in comparison was
highly toxic (ca. 60%). Upon reduction (PtIV!PtII) by GSH,
PtII-PW11 interacts with DNA, leading to apoptosis. The
hybrid exhibited also promising in vivo activity as it almost
completely reduced the tumor size of HT-29-bearing BALB/c
mice (dose = 0.8–2 mgkg@1) performing better than CDDP
without exhibiting body-weight-reducing effects. As Pt com-
plexes are known for their nephrotoxicity, the Pt level in the
rat kidney was determined, revealing that the treatment with
PtIV-PW11-DSPE-PEG2000 led to considerably lower Pt levels
than in the case of CDDP, rendering the hybrid an effective
alternative for cancer therapy.
The anticancer activity of other POM-based nanocompo-
sites is summarized in the Supporting Information, Table S16.
3. Proposed Mechanisms of the Anticancer Activity
of Polyoxometalates
3.1. Cell Penetration of Polyoxometalates
The antiproliferative activity of an anticancer drug is
directly associated with its degree of cellular uptake. It is well
accepted that POMs are able to penetrate cancer cells, as
many studies have experimentally confirmed their location
within the cytoplasmic space.[46, 99, 109–111,119] However, no con-
vincing data has been reported revealing the exact mecha-
nism. Owing to their large size and negative charge, POMs are
supposed to be rather unable to penetrate the largely
negatively charged cell membranes of mammalian cells.
POMs such as the Keggin-type were characterized as super
chaotropic agents with a surprisingly high tendency to adsorb
on neutral and hydrophilic surfaces, whereby POMs with
lower charge densities were more chaotropic.[120] Owing to
this feature, POMs exhibited destructive activity towards
model cell membranes by adsorbing to the vesicle surface,
followed by the formation of a stable POM–lipid conjugate,
which finally desorbs from the membrane (Figure 10).[121,122]
These desorption processes led to leaky membrane structures.
Studies with anionic lipids revealed that depending on the
charge density, the POM–lipid interactions can switch from
electrostatic to hydrophobic nature, owing to the charge
neutralization by cationic counterions.[123]
Nevertheless, it is still generally assumed that POMs are
mainly taken up by cells by some form of endocytosis.
Different POTs were traced within murine macrophage J774
cells revealing POM containing vacuoles within the cells,
wherefore, it was suggested that POMs might bind to
scavenger receptors and enter the cell by scavenger recep-
tor-mediated endocytosis.[124] Similarly, huge POMo nano-




CH3COO)30}] were found to be located within endosomes
that were evenly distributed in the cytoplasm of Hep-G2 cells,
supporting internalization by an endocytotic pathway.[119]
Monitoring of the FITC labeled {Eu(SiW11O39)2}–CMC
within HeLa cells showed that the nanoparticles were
Figure 10. Representation of the destructive interaction between POMs
and membranes. The POM adsorbs to the membrane surface and
forms a stable POM–lipid conjugate that desorbs from the membrane.
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preferably located in the perinuclear region in close proximity
to the nuclei.[98] Clathrin-mediated endocytosis was proposed
as POM-free chitosan nanoparticles are internalized by this
pathway; however, this was later excluded as the cellular
uptake of POM-CT was not inhibited by the clathrin inhibitor
chlorpromazine indicating a clathrin-independent pathway.[99]
Thus, macropinocytosis and caveolae-mediated endocytosis
were suggested as internalization pathways for, at least,
POM-CT hybrids as chitosan-DNA-poly(g-glutamic acid)
complexes are uptaken by these pathways.[125]
3.2. Proposed Modes of Action and Biological Targets of
Antitumoral Polyoxometalates
Figure 11 shows most of the putative mechanisms of
antitumoral POMs in a comprehensive Scheme. The first
suggested mechanism for the antitumor activity of POMs was
that by Yamase, which was already mentioned in the
introduction.[19] Briefly, repeated reduction/oxidation cycles
between the POM and cell components, most likely members
of the electron transport chain, are supposed to interfere with
ATP generation, which finally leads to apoptosis (Fig-
Figure 11. Illustration of most of the proposed modes of action of antitumoral POMs. a) POM induced inhibition of ATP synthesis by interfering
with the electron transfer chain (represented as dark blue entities, the inset shows a zoomed view of the chain). b) POM induced increase in
ROS-level (for example by oxidizing cell components) and depletion of the GSH pool (by GSH oxidation). c) POM induced enhancement of the
expression of pro-apoptotic components (Bax and Bim) and the reduction of the expression of anti-apoptotic components (bcl-2 and NF-kB).
d),e) Activation of the p53 and/or p38 pathway by POMs. Please note: the circles reading p38 and p53 do not represent the respective protein but
the pathways. f) Induction of apoptosis by direct DNA damage. g),h) POM-mediated inhibition of angiogenesis via interaction with bFGF and
VEGF leading to the disruption of the VEGF/bFGF-receptor interactions (receptors are indicated as yellow and brownish channels). Without
VEGF/bFGF-receptor binding, the ERK pathway cannot be activated leading to the breakdown of angiogenesis. i) Inhibition of ectonucleotidases
by POMs leads to a distortion in the concentrations of nucleotides (NTP, NDP, and NMP) and nucleosides (Ns), which negatively affects the
functioning of cancer cells. j) Inhibition of HDAC by POMs leads to the accumulation of acetylated histones, causing fatal changes in the
expression of genes. k) Inhibition of P-type ATPases has fatal effects on the cellular ion homeostasis. l) Decavanadate-induced mitochondria
membrane depolarization. m) Inhibition of other proteins that affect cell viability (for more details, see text of Section 2.3.1 and 3.2.5, and
references therein). n) POM hybrids loaded with siRNA (siRNA is depicted as red RNA structure) downregulate HIF-1, leading to the impairment
of angiogenesis and the adaptation of cancer cells to the hypoxic environment. o) Immunostimulating activity of POMs by promoting the
expression of antibodies and immune-related components (for example, NK cells). The figure depicts the activation of NK cells via antibody
binding enhancing the recognition of tumor cells (antigens are depicted as purple triangles) by NK cells. Dotted lines indicate that the reason of
activation/deactivation (for example, enhanced/decreased expression) of certain components is not known. The release of cytochrome c (purple
circle) triggers the apoptotic machinery of the cell, which ultimately activate the final executers of apoptosis (caspases).
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ure 11a). The theory is widely accepted, as a series of studies
revealed a putative correlation between the cytotoxicity and
the redox potential of bioactive POMs.[38–44] This correlation is
a weak one and only applies to very closely related structures,
as other factors like size, structure, and composition play also
a significant role. In general, there is no unambiguous
correlation between the anticancer activity of POMs and
parameters such as POM size, total net charge, charge density,
oxidation power, and archetype.
3.2.1. Activation of Cell Death Pathways
Apoptosis, necrosis, and autophagy are types of cell death,
which are generally highly sophisticated processes including
complex signaling cascades that are tightly regulated. Accord-
ing to Section 2, a number of POMs induced apoptosis by the
mitochondrial (intrinsic) pathway as no study describes, for
example, the involvement of a death receptor, which is
a hallmark for extrinsic apoptosis. The reason for this is that
most POMs mainly induced “internal damage” by oxidative
stress, which is signaled to mitochondria (Figure 11b). Some
POMs like the Wells–Dawson POM are able to induce
apoptosis by affecting the expression of cell death regulators,
for example, by increasing the amount of the pro-apoptotic
proteins Bax and Bim (Figure 11c).[126,127] Other POMs, such
as Krebs-type, do also reduce the expression of the anti-
apoptotic protein bcl-2 and the transcriptional factor NF-kB
(Figure 11 c).[33, 34] Active NF-kB is responsible for the expres-
sion of genes that protect the cell from undergoing apoptosis,
however, many tumor types have a constantly active NF-kB
and therefore its inhibition represents a promising approach
in cancer therapy. Furthermore, Krebs-type tungstobismu-
thates are able to increase the expression of p53 activating
apoptosis partially by this pathway (Figure 11 d).[33] The
tumor suppressor p53 is a transcription factor that induces
anti-carcinogenesis events such as cell growth arrest and
inhibition of angiogenesis, making it the guardian of the
genome and one of the most promising targets as about 50%
of human cancers are thought to be related to p53 muta-
tions.[128] Some POMs like the CoII containing Krebs-type
(H2im)2[(W(OH)2)2(Co(H2O)3)2(Na4(H2O)14)(BiW9O33)2] are
able to enhance the activation of caspase-3, the final execu-
tioner of apoptosis.[35, 127] Na7[Cr
IIICuIIW11O39] was observed to
induce the upregulation of both cytochrome c and activated
p38 in human ovarian SK-OV-3 cancer cells (Figure 11 e),
despite its very low anticancer activity (IC50 = 1.87 mm).
[127]
Cytochrome c is an essential component of the electron
transport chain but plays also a decisive role in apoptosis as its
release from the mitochondria into the cytosol upon apoptotic
stimuli triggers apoptosis.[129] Thus, POM-induced overex-
pression of cytochrome c can promote cell death. p38 is
a mitogen-activated protein kinase (MAPK) that has onco-
genesis suppressing properties as it is required for dormancy,
that is, inhibition of the cell proliferation upon certain stress
stimuli.[130] Furthermore, Na7[Cr
IIICuIIW11O39] is also able to
trigger autophagy, which means that two cell death pathways
can run in parallel. The same was observed for PM-17 as it
induced apoptotic and autophagic cell death in vitro and







8@ exhibited remarkable activity against
cancerous K-562 (leukemia) and Hep-G2 (liver) cells (IC50 =
0.4 mm for both) by affecting lysosomes in vitro, which led to
the induction of both apoptosis and autophagy.[131] The
autophagy inducing property might originate from the AsIII
containing unit as As2O3 is known to induce autophagy in
leukemia cells by increasing the level of Beclin-1, a critical
regulator of autophagy.[132]
3.2.2. DNA Interaction
One of the main stimuli inducing intrinsic apoptosis is
DNA damage. Therefore, the anticancer activity of a series of
POMs and POM-based hybrids was associated with DNA
lesions but mainly induced indirectly as the negative charge of
both molecules is supposed to prevent direct electrostatic
interactions. However, some POM-based structures were
found to directly interact with DNA (Figure 11 f), for
example, [(CpTi)3SiW9O37]
7@ interacts strongly with DNA,
most likely via its CpTi moiety.[43, 47] These results were
confirmed by the group of Habibi, which investigated the
behavior of different CpM-substituted Keggin POTs (M =
ZrIV, TiIV, FeII) towards ctDNA and suggested a direct but
noncovalent groove or outside stacking binding mode for the
POM.[46] Later, the number of POMs directly interacting with
ctDNA was extended, including [PV2Mo10O40]
5@ and
[V18O42(H2O)]
12@.[31, 109–111] Despite the suggested groove or
outside stacking interaction, the exact POM binding mecha-
nism remains elusive. Another study investigating the inter-
action between heptamolybdate [Mo7O24]
6@ and the DNA
model bis(p-nitrophenyl)phosphate showed that the POM
was able to cleave the phosphodiester bond by a yet unknown
mechanism.[133]
3.2.3. Inhibition of Angiogenesis
Angiogenesis describes the formation of new blood
vessels, a vital process in cell growth.[134] As cancer cells are
rapidly dividing, tumors need special blood supply to provide
oxygen and other nutrients to continue their abnormal
growth. Thus, they induce angiogenesis by activating various
growth factors such as the vascular endothelial growth factor
(VEGF) and the basic fibroblast growth factor (bFGF), which
stimulate the formation of blood vessels. The inhibition of
angiogenesis promoting factors is a potential approach in
cancer therapy. A series of POMs, including lacunary and
fully saturated Keggin, sandwich Keggin, and Wells–Dawson
structures, interact strongly with bFGF leading to the
inhibition of its proliferation promoting activity in
HUVECs.[135, 136] Independent of the charge, Wells–Dawson
POMs were most efficient in binding bFGF and therefore it
was assumed that the POM structure determines the affinity
towards bFGF. Competition assays with suramin, which is
known for its angiosuppressive properties, and heparin, an
activity enhancer and inhibitor of bFGF, revealed that POMs
bind in the vicinity of the heparin binding site, which is rich in
positively charged amino acids. According to the dimensions
of the proposed binding site, Wells–Dawson structures are
supposed to fit better into it than the smaller Keggin ions,
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which might explain the differences in binding affinity
(Figure 12). POM binding might interfere with the ability of
bFGF to interact with its receptors, which is required for its
angiogenesis promoting function (Figure 11g).




VO4(CH3COO)30}] exhibited astonishing anti-
cancer activities against some cancer cell lines with high
selectivity towards Hep-G2 cells (IC50 = 9–55 mgmL
@1) mainly
by inhibiting angiogenesis (Supporting Information, Table S1,
described as Mo-compounds 1–3).[119] The Mo-nanoparticles
impaired the formation of blood vessels by inhibiting key
processes of angiogenesis, namely VEGF-induced prolifera-
tion, migration, and tube formation of endothelial cells
(HUVECs) and neovascularization on CAM (chorio-allan-
toic membrane). Furthermore, the level of NO, a mediator of
angiogenesis, was also significantly reduced in the presence of
the POMos as was the VEGF-induced phosphorylation of
signal-regulated kinase 1 and 2 (ERK1/2) and phosphoinosi-
tide 3-kinase (AKT), signaling processes normally associated
with the promotion of angiogenesis (Figure 11h).
3.2.4. Interaction with Proteins
Owing to their negative charge and their tendency to bind
to neutral or hydrophilic surfaces, POMs interact with an
array of proteins.[138] Ectonucleotidases are membrane-asso-
ciated enzymes that hydrolyze extracellular nucleotides to the
respective nucleosides and are thus involved in numerous
physiological and pathological processes.[139] They can be
subdivided into four families, ectonucleoside triphosphate
diphosphohydrolases (NTPDases), ectonucleotide pyrophos-
phatases (NPPs), alkaline phosphatases (APs), and ecto-5’-
nucleotidase (eN). POMs are potent inhibitors of ectonu-
cleotidases, with some of them being superior to known
inhibitors (Figure 11 i; Supporting Information,
Table S17).[140] Crystallographic studies investigating the
interaction of decavanadate, metatungstate, octa-, and hep-
tamolybdate with rat and bacterial NTPDase1 revealed that
decavanadate and heptamolybdate bind either at the periph-
ery (rat NTPDase) or deep inside the active site cleft
(bacterial NTPDase) of the enzyme at positively charged
patches, where they interact with substrate binding residues
(Figure 13).[141, 142] Therefore, it was suggested that enzyme
inhibition occurs by blocking the nucleotide-active site
interaction. Octamolybdate (Figure 1 i) is located at the
entrance of the active site cleft and could also interfere with
substrate binding. Interestingly, one of the most potent
inhibitors, metatungstate, binds distantly from the active site
and therefore the inhibitory effect might result from POM-
mediated destabilization of the entire enzyme structure.
The inhibition of human NTPDase1, also known as CD39,
is of particular pharmacological interest as it converts ATP
into adenosine, which is an important molecule in the
suppression of the antitumor T cell response and therefore
it is exploited by tumors to overcome immune response.[143]
NTPDase1 inhibition by metatungstate led to a significant
in vivo suppression of murine B16-F10 melanoma (inhibition
rate ca. 86.1 %, 5 mg kg@1) and to a moderate reduction of
murine colon adenocarcinoma (MCA-38, ca. 27.3 %,
5 mgkg@1) in mice.[144] Metatungstate was not active in
NTPDase1 deficient tumor-bearing mice confirming
NTPDase1 inhibition as the mode of action. Further studies
investigating the effect of several POMs on human
NTPDase1-3, NPP1-3, and rat eN revealed that POMs were
most efficient in inhibiting NTPDase1-3 and NPP1, with some
of them exhibiting inhibition constants in the nanomolar
range (Supporting Information, Table S17).[145, 146] [Co4(-
H2O)2(PW9O34)2]
10@ was identified as a very potent inhibitor
of human NTPDase1-3 (Ki = 4, 20 and 100 nm), being the
most potent inhibitor of human NTPDase1 described to date.
POMs are also potent inhibitors of tissue specific alkaline
phosphatase (TSAP, from calf intestine) and of tissue non-
specific alkaline phosphatase (TNSAP, from pork and
human), with some of them being active at nanomolar
concentrations (Supporting Information, Table S17).[145,147]
Regarding human TNSAP, [P6W18O79]
20@ (Ki = 2.3 mm) is the
most potent inhibitor.[145] APs are highly expressed by
osteoblasts to hydrolyze inorganic pyrophosphate for bone
mineralization. This osteoblastic activity is remarkably
increased in prostate cancer, which preferentially metasta-
Figure 12. Putative POM-binding site of bFGF. a) Crystal structure of
human bFGF (PDB entry 1BFF[137]) with the putative binding site being
marked by a red circle. Side chains of amino acids that potentially
contribute to heparin binding are shown as sticks. b) Coulombic
surface representation of bFGF is illustrated with blue surfaces
representing regions exhibiting a positive potential, whereas gray and
red surfaces possess neutral and negative potentials, respectively.
c) Zoom view and dimensions of the putative POM-binding site.
d) Polyhedra structures and dimensions of the Keggin and Wells–
Dawson anions for easier comparison. Blue polyhedra are {MO6},
green polyhedra {XO4}, green sticks carbon, dark blue sticks nitrogen,
red sticks and spheres oxygen.
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sizes to bone, leading to dysregulated bone formation.[148]
Therefore, the inhibition of APs by POMs could be a promis-
ing strategy in the treatment of metastatic prostate cancer.
A series of POMs were tested on several kinases showing
high specificity for protein kinase CK2.[149] Protein kinases
catalyze the phosphorylation of proteins leading to their
modification, that is, change in enzymatic activity, cellular
location, or interaction behavior to regulate cellular processes
such as signal transduction. Protein kinase CK2 is upregulated
in many cancer types and thus associated with their increased
proliferation rate and ability to suppress apoptosis.[150] Deri-
vates of the Wells–Dawson (IC50 = 1–70 mm) and Preyssler
archetype (IC50 = 1–5 mm), and giant POM anions (IC50 = 8–
70 mm), showed moderate to high inhibition of CK2. In
contrast, smaller POMs such as Keggin derivates (IC50 = 60–
1000 mm) were less active indicating that the POM structure
roughly determines the inhibitory effect. Further analysis
revealed that the POM binding site is located at an exposed
site outside the ATP/peptide binding pocket and the catalytic
cleft from where the POM could however interfere with the
activation loop of CK2 (Supporting Information, Fig-
ure S4).[151]
A high-throughput screening study assaying 400 POMs
was performed to identify potential histone deacetylase
(HDAC) inhibitors revealing [{(n-Bu)Sn(OH)}3GeW9O34]
4@
as the most efficient HDAC-inhibitor (IC50 = 1.1 mm) (Fig-
ure 11 j).[48] HDAC is an enzyme that is responsible for the
removal of the acetyl group from an acetylated lysine making
histones to wrap DNA more tightly. This is an essential
process as DNA expression is regulated by the acetylation
and deacetylation of histones. HDACs are involved in cell-
cycle progression and differentiation and therefore distur-
bances in HDAC encoding genes are linked to tumor
development rendering them promising targets.[152] This
rationale was confirmed by the in vitro and in vivo anticancer
activity of [{(n-Bu)Sn(OH)}3GeW9O34]
4@, which were dis-
cussed in Section 2.2.1.
Several POMs like [V10O28]
6@ or [P2W18O62]
6@, which are
known to exhibit antitumor activity, have also been described
as potent P-type ATPase inhibitors (Figure 11 k).[153–155] P-
type ATPases are a large group of ion pumps that play
a crucial role in maintaining the ionic balance in cells and
therefore have been described as potential molecular targets
for the treatment of several diseases. P-type ATPases like
Na+/K+-ATPase also act as signal transducer and their activity
was found to be significantly changed in tumors making Na+/
K+-ATPase inhibitors particularly interesting as anticancer
drugs.[156] Therefore, the reported anticancer activity of some
POMs, especially that of decavanadate and other POVs, may
partially derive from their ability to inhibit P-type ATPases.
However, POM-mediated P-type ATPase inhibition is not
tumor-cell-selective. Besides this, decavanadate induces mito-
chondria membrane depolarization and inhibits mitochon-
drial oxygen consumption in vivo rendering mitochondria the
main toxicological target for decavanadate (Figure 11 l).[157]
The mechanism behind the anticancer activity of POM-
bisphosphonate (POM-BP) complexes, which were discussed
in Section 2.2.2, is supposed to be the inhibition of the
prenylation of important proteins like the Ras subfamily,
which belong to the class of small GTPase. The Ras genes are
the most common oncogenes in human cancer, and point
mutations within these genes result in the accumulation of
activated Ras, which in turn causes a permanent cell growth-
promoting signaling, ultimately leading to cancer.[158] There-
fore, the Ras pathway is a promising biological target. BPs
like Zol are known to inhibit farnesyl diphosphate synthase,
an enzyme supplying precursors for the biosynthesis of
isoprenoids that are essential for prenylation. In the same
way, POM-BP complexes could inhibit the prenylation of
(mutated) Ras, preventing it from reaching its full function-
ality, and thus impairing tumor growth. This mechanism was
supported by the finding that the addition of geranylgeraniol
(GGOH), an isoprenol that is also used for protein prenyla-
tion, impaired the antitumor activity of Mo-based POM-BP
complexes as prenylation was restored. Interestingly, the
Figure 13. POM-binding sites of NTPDase1 from Legionella pneumo-
phila. The structure of bacterial NTPDase1 consists of two domains
(cyan and green cartoon) with the interface forming the active site
cleft. The depicted structure is taken from PDB entry 4BVO[142] as
model example. The interacting amino acid residues are shown as
sticks. Light blue spheres are tungsten, cyan spheres molybdenum,
gray spheres vanadium, cyan/green sticks carbon, dark blue sticks
nitrogen, red sticks oxygen. Dashed lines represent POM–protein
interactions. Note that octamolybdate forms a covalent bond with
a serine (Ser 127).
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activity of V-containing BP complexes was not affected by
GGOH, suggesting that the activity of these complexes is
governed by the POV unit and thus follows a POV-based
mode of action.
Besides the discussed biomacromolecules, POMs interact
with an array of other important proteins including phospha-
tases, kinases, polymerases, proteases, actin, sulfotransferases,
and sialyltransferases (Figure 11m).[28, 138,159–162] POM-medi-
ated inhibition of certain enzymes has a specific effect on the
cell viability and may thus contribute to pharmacological
activities. Some of these enzymes are membrane-associated
proteins of which targeting is facilitated as the POM does not
has to enter into the cytoplasmic space for inhibition.
3.2.5. Other Mechanisms
The anticancer activity of the {Gd(W5O18)2}–CTsiRNA
system is on the one hand based on the radiosensitizing
effect of the Gd-POM, leading to the cellular generation of
ROS upon X-ray irradiation and on the other hand by the
HIF-1a down-regulating effect of the siRNA (Figure 11 n).
Besides increasing the ROS level, the POM oxidizes GSH
preventing the cancer cell from counteracting the oxidative
stress. The inhibition of HIF-1a leads to the depletion of
downstream proteins, which makes the cancer cell more
amenable to the lethal hypoxic environment. The expression
of the angiogenesis promoting factors VEGF and c-Met were
remarkably decreased upon HIF-1a inhibition, leading to an
increased vulnerability of the cells owing to the detriment of
the development of new blood vessels.[100]
The FeIII containing sandwich POM [Fe(HPW7O28)2]
13@
exhibited moderate in vitro cytotoxicity to a series of cancer
cells (Supporting Information, Table S2) but showed promis-
ing in vivo activity by inhibiting the tumor growth in S180
sarcoma bearing mice (inhibitory rate = 45.7 % at
80 mg kg@1).[163] The in vivo activity derived mainly from the
ability of the POM to enhance the immune response in tumor-
bearing mice. The activation of the host immune response has
been recognized as a promising approach in the combat
against tumors.[164] The POM significantly increased the
proliferation of splenocytes, the activity of natural killer
(NK) cells and cytotoxic T lymphocytes (CTLs), and pro-
moted the production of the Type 1 helper cytokines
interleukin-2 (IL-2) and interferon-g (IFN-g). Furthermore,
the serum antigen-specific antibody level (IgG2a and IgG2b)
was enhanced upon POM treatment. All these results indicate
that [Fe(HPW7O28)2]
13@ has immunomodulatory activity,
making this POM a potential drug for immunotherapy
(Figure 11 o).
4. Summary and Outlook
A series of POMs and POM-based hybrid systems possess
considerable potential as metallodrugs in the treatment of
cancer as evidenced by in vitro and in vivo studies. Owing to
the lack of clear correlations between the observed anticancer
activities and any structural or chemical POM feature, it is
quite impossible to anticipate the bioactivity of a given POM.
In general, the bioactivity of purely inorganic POVs or
vanadium-containing POMs was higher than that of POMos
and POTs. However, the clinical application of POMs is
restricted because of some major drawbacks: POMs are
generally highly toxic[17, 18, 22] and most POM-archetypes are
thermodynamically and kinetically unstable under physiolog-
ical conditions.[77, 106, 165] Furthermore, naked POMs possess
rather low cell penetration ability and their promiscuous
protein binding leads to low selectivity. Despite these
limitations, POMs are still considered valuable bioactive
agents, as nearly every molecular property that affects their
biological reactivity can be altered and their surface can be
organically modified or encapsulated by biocompatible
molecules, enabling the synthesis of multifunctional and
cell-penetrating hybrid POMs that overcome most of the
aforementioned drawbacks. Grafting of organic molecules
onto the POM core or incorporation of bioactive transition
metals into the POM framework had partially immense
effects on the bioactivity of the system. However, the
incorporation of POMs into nanocomposites is clearly more
effective in terms of increasing the POM stability and
decreasing its inherent toxicity. POM-based hybrids and
nanocomposites containing a cell targeting molecule (for
example, a receptor agonist) or a further bioactive compound
were especially efficient in most cases. In general, the
biological and pharmacokinetic properties of POM-based
nanocomposites seem to be superior to that of just organically
functionalized POMs.
Fundamental questions regarding the mechanisms behind
the POM-mediated antiproliferative effects remain largely
unanswered. Although a series of possible mechanisms and
potential targets were proposed, the exact mode of action
remains unclear. With the existing methods it is almost
impossible to pinpoint the POM-induced effect that finally
leads to cell death, as cell death is associated with a variety of
signaling pathways that crosstalk heavily and involve a ple-
thora of signaling molecules. Due to their multifunctional
character, POM-based systems possess a large repertoire of
possibilities to inhibit tumors and therefore their mode of
action will probably not be explained by one strict mechanism
but rather by multiple interactions interfering with a number
of cellular processes. Owing to the low stability of most POM
archetypes, more and more researchers propose that mono-
meric species or unidentified POM fragments are responsible
for the observed biological effects.[79, 80,92] According to this,
the POM might rather act as a carrier of these active species
that upon reaching the site of action releases the toxic
payload. Therefore, it is important to develop reliable
methods that allow the unambiguous identification of the
bioactive species. In this way, whether the activity of POMs
correlates with their propensity to dissociate could be
investigated. In general, this field requires an immense
experimental effort and the development of novel and
improved methods to elucidate the mechanism behind the
anticancer activity of POMs. Future research will focus on the
identification of new targets and the design of novel POM
hybrids as they are currently the most efficient (POM-
containing) compounds regarding the biological activity,
toxicity, and pharmacokinetic properties. To meet all of
Angewandte
ChemieReviews
2996 www.angewandte.org T 2019 The Authors. Published by Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim Angew. Chem. Int. Ed. 2019, 58, 2980 – 2999
these upcoming tasks and to pave the way for POMs as next-
generation anticancer drugs, interdisciplinary cooperation
between chemists, biochemists, crystallographers, pharma-
cists, and physicians is required.
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